Three things health execs need to know about CAR T-cell therapy – ModernMedicine
|
Three things health execs need to know about CAR T-cell therapy
ModernMedicine Locke notes that these were “very refractory patients” and historical data holds that they should have no more than six months to live and a less than one in 10 chance of having a complete disappearance of their lymphoma. With one infusion of CAR T … |
